Get the Stockscreener App
87.38
4.14%
-3.77
Rhythm Pharmaceuticals Inc stock is traded at $87.38, with a volume of 1.62M.
It is down -4.14% in the last 24 hours and down -10.90% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
See More
Previous Close:
$91.15
Open:
$88.84
24h Volume:
1.62M
Relative Volume:
2.06
Market Cap:
$5.97B
Revenue:
$189.76M
Net Income/Loss:
$-196.54M
P/E Ratio:
-28.11
EPS:
-3.1087
Net Cash Flow:
$-156.63M
1W Performance:
-6.57%
1M Performance:
-10.90%
6M Performance:
-9.19%
1Y Performance:
+73.93%
1-Day Range:
$82.00
$90.50
1-Week Range:
$82.00
$94.94
52-Week Range:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
87.38 | 6.22B | 189.76M | -196.54M | -156.63M | -3.1087 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | RBC Capital Mkts | Outperform |
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Early FDA, Japan Filings For Setmelanotide In Hypothalamic Obesity Might Change The Case For Investing In Rhythm Pharmaceuticals (RYTM) - simplywall.st
Institution Moves: Is Rhythm Pharmaceuticals Inc vulnerable to short sellers2026 Price Targets & Long Hold Capital Preservation Plans - baoquankhu1.vn
Wells Fargo Maintains Overweight, Raises Price Target for RYTM t - GuruFocus
Wells Fargo raises Rhythm Pharmaceuticals price target on revenue - Investing.com
598,247 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Purchased by Capital Research Global Investors - MarketBeat
(RYTM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After New Trial Data Earnings And Financing Updates - Sahm
Rhenman & Partners Asset Management AB Purchases Shares of 35,000 Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) CAO Sells $502,789.84 in Stock - MarketBeat
Rhythm Pharmaceuticals (RYTM) Is Down 8.2% After Positive TRANSCEND Data And FDA sNDA Progress - Sahm
Proposed sale of 64,540 common shares under registered plan (RYTM) - Stock Titan
HC Wainwright Issues Negative Estimate for RYTM Earnings - MarketBeat
Rhythm Pharmaceuticals (RYTM) CAO exercises RSUs, withholds shares for taxes - Stock Titan
Jefferies reiterates Rhythm Pharmaceuticals stock rating on trial outlook By Investing.com - Investing.com Canada
RYTM (NASDAQ: RYTM) brokered notice for 35,460-share sale on 03/03/2026 - Stock Titan
Does Rhythm Pharmaceuticals (RYTM) Share Price Reflect Its Obesity Treatment Potential Today - simplywall.st
Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright - Yahoo Finance
Rhythm Pharmaceuticals (RYTM) CFO exercises options, acquiring 6,099 shares - Stock Titan
Canaccord Genuity Lowers Price Target for RYTM, Maintains Buy Ra - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $140.00 at Canaccord Genuity Group - MarketBeat
HC Wainwright Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $110.00 - MarketBeat
RYTM: HC Wainwright & Co. Lowers Price Target Despite Maintainin - GuruFocus
Why Is Rhythm Pharmaceuticals Stock Trading Higher Today?Rhythm Pharmaceuticals (NASDAQ:RYTM) - Benzinga
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Robust Analyst Ratings Signal Potential 51.69% Upside - DirectorsTalk Interviews
Canaccord lowers Rhythm Pharmaceuticals stock price target to $140 - Investing.com
Canaccord lowers Rhythm Pharmaceuticals stock price target to $140 By Investing.com - Investing.com Canada
Rhythm Says New Late-Stage Data for Obesity Drug Shows Strong Weight Loss, Hunger Reduction - marketscreener.com
Rhythm Highlights Positive Phase 3 Data in Hypothalamic Obesity - TipRanks
Rhythm Pharmaceuticals posts 18.8% placebo‑adjusted BMI reduction in TRANSCEND Phase 3 52‑week data - TradingView
Rhythm Pharmaceuticals (Nasdaq: RYTM) adds positive Phase 3 HO data ahead FDA PDUFA - Stock Titan
Rhythm Pharmaceuticals (RYTM) Reveals Promising Phase 3 Trial Da - GuruFocus
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Pullback In Share Price - Yahoo Finance
Rhythm Pharmaceuticals Reports Positive 52-Week Data from Phase 3 TRANSCEND Trial of Setmelanotide for Acquired Hypothalamic Obesity - Quiver Quantitative
Rhythm Pharmaceuticals says PDUFA goal date for setmelanotide is March 20, 2026 - marketscreener.com
Rhythm Pharmaceuticals Says PDUFA Goal Date For Setmelanotide Is March 20, 2026 - TradingView
Rhythm Pharmaceuticals Announces Additional Positive Data - GlobeNewswire
Artisan Partners Limited Partnership Buys 62,362 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Obesity drug shows 18.8% BMI edge, backing first FDA bid in acquired HO - Stock Titan
RYTM SEC FilingsRhythm Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Rhythm Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RYTM) 2026-02-27 - Seeking Alpha
Wells Fargo & Company Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $136.00 - MarketBeat
Rhythm Pharmaceuticals (RYTM) Price Target Lowered by Wells Farg - GuruFocus
RBC Capital Adjusts Price Target on Rhythm Pharmaceuticals to $140 From $145, Maintains Outperform Rating - marketscreener.com
Citizens Jmp Raises Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $176.00 - MarketBeat
Is Rhythm Pharmaceuticals Inc. stock risky to hold now2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - mfd.ru
Needham & Company LLC Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Guggenheim Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
RYTM Stock Update: Guggenheim Maintains 'Buy', Raises Price Targ - GuruFocus
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2025 Earnings Call Transcript - Insider Monkey
Guggenheim raises Rhythm Pharmaceuticals stock price target on guidance By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):